Cardiol Therapeutics Inc. (TSX:CRDL)
Canada · Delayed Price · Currency is CAD 1.670
+0.060 (3.73%)
Jul 21, 2025, 4:00 PM EDT
Cardiol Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
133.07M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries | 1.64B |
| Sienna Senior Living | 896.45M |
| dentalcorp Holdings | 1.58B |
| WELL Health Technologies | 990.34M |
| Extendicare | 1.47B |
| Cronos Group | 179.08M |
| Trulieve Cannabis | 1.71B |
| Curaleaf Holdings | 1.89B |
Cardiol Therapeutics News
- 7 weeks ago - Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders - Newsfile Corp
- 7 weeks ago - Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Newsfile Corp
- 3 months ago - Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp
- 3 months ago - Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile Corp
- 5 months ago - Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile Corp
- 5 months ago - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure - Newsfile Corp
- 5 months ago - Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts - Seeking Alpha